Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples

Abstract

Introduction: The therapeutic scenario of Oncology is enriching of innovative agents which are determining an increase in public expenditure because of their high cost. In Italy, a web-based government Registry is used to monitor the clinical use of these drugs and, in later phases, to obtain funds reimbursement according to specific economic agreements with companies. Methods: A health policy expert Pharmacist was included in the multidisciplinary team of the Department of Abdominal Oncology of the National Cancer Institute (NCI) of Naples “G. Pascale Foundation” in order to improve the management of the Registry for oncologic drugs monitoring. Pharmacist activities were: basal data registration, prescription appropriateness, drug request, response monitoring, toxicity reporting, follow-up, reimbursement request. These activities were conducted in strict interrelation with clinicians. The source of data were medical records and a web-based national reimbursement platform. The analysis of the economic impact of this strategy was descriptive and it was indicated as resources recovery comparing 2 years: 2015 vs. 2016. The currency reference used was the Euro (€). Results: A total of 932 patients were followed-up and registered, 365 treatments are ongoing at the Department of Abdominal Oncology (NCI of Naples, Italy). The most prescribed biologic drug in advanced gastrointestinal cancers was bevacizumab. Compared to the year 2015, in 2016 we recorded a strong increase of reimbursements: EUR 881.712,42 vs. EUR 214.554,98. Conclusions: We suggest that the reimbursement process can be improved when a health policy reimbursement professional Pharmacist is integrated in the multidisciplinary team along with clinicians.

Knowledge management tools and mechanisms for evidence-informed decision-making in the WHO European Region: a scoping review

“…Twenty-one studies focused on the role of registries in decision-making (Additional file 5 : Appendix 5). Cancer registries, at the national and regional levels, received special attention among registries targeting specific diseases and were found to help establish public health priorities, guide resource allocation, inform decisions regarding reimbursement, access and care delivery and support planning and evaluation of health services [ 27 – 31 ].…”

International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market

“…As a potential consequence, PBRSAs accounted for 29.8 percent of the total amount of €41.1 million pharmaceutical budget under all types of risk-sharing agreements in Italy in 2012 (26). Up to 2018, there are 130 innovative drugs monitored on the AIFA registries (41).…”